New enhancer protein expands IDT's market-leading portfolio of HDR reagents, empowering cell and gene therapy developers to accelerate discoveries ...

Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. DNA synthesis is vital to several processes in biopharmaceutical innovation, including the ...

Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

The death of William (Bill) Rutter at the grand old age of 97 in July reminded me to remember not only him, but several of the other pioneers of our industry—lest we should forget them.

The rDNA debate was initiated by the molecular biologists leading the research, and within a year expanded to include the public. Fourteen key participants representing molecular biologists, ...

THE STRUCTURE AND FUNCTION OF RECOMBINANT HUMANIZED TYPE III COLLAGEN AS WELL AS ITS RELATED PRODUCT approved by CHINA NMPa for COSMETICS USE (ADAPTED FROM THE AUTHORS’ PUBLICATION IN Biochemical and ...